Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01689025 · ClinicalTrials.gov registry record · Phase 1
An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Terminated
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT01689025 is a Phase 1 study that was terminated before completion, run by Novo Nordisk A/S. The registered enrollment target is 10 participants.
The verdict
NCT01689025, a Phase 1 study, was terminated before completion, sponsored by Novo Nordisk A/S.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This trial is conducted in Europe and the United States of America (USA). The aim of the trial is to investigate the safety and tolerability of NNC0114-0006 in subjects with systemic lupus erythematosus (SLE) concomitantly treated with stable background therapies.
Interventions
- DRUG placebo
- DRUG NNC0114-0006
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2012-09 |
| Est. Completion | 2014-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01689025
The ClinicalTrials.gov registry entry for NCT01689025 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01689025 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01689025 about?
NCT01689025 is a clinical study titled "An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)". This trial is conducted in Europe and the United States of America (USA). The aim of the trial is to investigate the safety and tolerability of NNC0114-0006 in subjects with systemic lupus erythematosus (SLE) concomitantly treated with stable background therapies.
What is the current status of trial NCT01689025?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2012-09. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01689025?
The interventions under investigation include: placebo (DRUG), NNC0114-0006 (DRUG).
Who is sponsoring clinical trial NCT01689025?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.